imvanex
bavarian nordic a/s - modificeret vaccinia ankara - bavarian nordic (mva-bn) virus - smallpox vaccine; monkeypox virus - andre virale vacciner, - active immunisation against smallpox, monkeypox and disease caused by vaccinia virus in adults (see sections 4. 4 og 5. brug af denne vaccine bør være i overensstemmelse med de officielle anbefalinger.
vermox 100 mg tabletter
chemvet pharma aps - mebendazol - tabletter - 100 mg
nulibry
tmc pharma (eu) limited - fosdenopterin hydrobromide dihydrate - metal metabolism, inborn errors - andre alimentary tract and metabolism produkter, - nulibry is indicated for the treatment of patients with molybdenum cofactor deficiency (mocd) type a.
livmarli
mirum pharmaceuticals international b.v. - maralixibat chloride - alagille syndrome - other drugs for bile therapy - livmarli is indicated for the treatment of cholestatic pruritus in patients with alagille syndrome (algs) 2 months of age and older.
venlafaxin "actavis" 150 mg depotkapsler, hårde
actavis group ptc ehf. - venlafaxinhydrochlorid - depotkapsler, hårde - 150 mg
venlafaxin "actavis" 75 mg depotkapsler, hårde
actavis group ptc ehf. - venlafaxinhydrochlorid - depotkapsler, hårde - 75 mg
venlafaxin "medical valley" 150 mg depottabletter
medical valley invest ab - venlafaxinhydrochlorid - depottabletter - 150 mg
venlafaxin "medical valley" 225 mg depottabletter
medical valley invest ab - venlafaxinhydrochlorid - depottabletter - 225 mg
vyndaqel
pfizer europe ma eeig - tafamidis - amyloidose - andre narkotika stoffer - vyndaqel er indiceret til behandling af transthyretinamyloidose hos voksne patienter med fase 1-symptomatisk polyneuropati for at forsinke perifer neurologisk nedsat funktion.
atriance
sandoz pharmaceuticals d.d. - nelarabin - forløber t-celle lymfoblastisk leukæmi-lymfom - antineoplastiske midler - nelarabine er indiceret til behandling af patienter med t-celle akut lymfoblastær leukæmi (t-all) og t-celle lymphoblastic lymphoma (t-lbl), hvis sygdommen ikke har reageret eller har fået tilbagefald efter behandling med mindst to kemoterapi regimer. due to the small patient populations in these disease settings, the information to support these indications is based on limited data.